Skip to main content

A Phase I study to evaluate the saftey, phamocokinetics and pharmacodynamics of JNJ-42756493 a pan-fibroblat growth factor receptor.

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Janssen Research & Development, LLC

Start Date

August 1, 2014

End Date

June 18, 2018
 

Administered By

Duke Cancer Institute

Awarded By

Janssen Research & Development, LLC

Start Date

August 1, 2014

End Date

June 18, 2018